1-5 of 5
Daniel S Pereira, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics

William Casey Wilson, PhD, John Richards, PhD, Robyn J Puro, PhD, Gabriela Andrejeva, PhD, Ben J Capoccia, PhD, Mike J Donio, Ronald R Hiebsch, BS, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-139655
Published: 2020
Journal Articles

Pre-Clinical Combination of AO-176, a Highly Differentiated Clinical Stage CD47 Antibody, with Either Azacitidine or Venetoclax Significantly Enhances DAMP Induction and Phagocytosis of Acute Myeloid Leukemia

Mike J Donio, W. Casey Wilson, PhD, Isra Darwech, Gabriela Andrejeva, PhD, Benjamin J Capoccia, PhD, Robyn J Puro, PhD, Arun K Kashyap, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-140528
Published: 2020
Journal Articles

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

John Richards, PhD, Myriam N Bouchlaka, BS,PhD, Robyn J Puro, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, W. Casey Wilson, PhD, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1844.
https://doi.org/10.1182/blood-2019-126298
Published: 2019
Journal Articles

Therapeutic Potential of AO-176, a Next Generation Humanized CD47 Antibody, for Hematologic Malignancies

W. Casey Wilson, PhD, Myriam N Bouchlaka, BS, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, Robyn J Puro, PhD, Alun J Carter, PhD, Prabir Chakraborty, PhD, Pamela T Manning, PhD, Robert W Karr, MD, Vicki Sung, PhD, Daniel S Pereira, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4180.
https://doi.org/10.1182/blood-2018-99-118456
Published: 2018
Journal Articles

AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts

Nandini Rudra-Ganguly, PhD, Christine Lowe, Cyrus Virata, Monica Leavitt, Liqing Jin, MD, Brian Mendelsohn, PhD, Josh Snyder, Hector Aviña, Chunying Zhang, Deanna L Russell, Michael Mattie, PhD, Peng Yang, PhD, Baljinder Randhawa, Gao Liu, Faisal Malik, Misty Vest, Joseph D Abad, Christopher C Kemball, PhD, René Hubert, PhD, Sher Karki, PhD, Banmeet Anand, PhD, Zili An, MD, Jeanette Grant, PhD, John E. Dick, PhD, Fernando Doñate, PhD, Kendall Morrison, PhD, Pia Challita-Eid, PhD, Ingrid B Joseph, DVM, PhD, Daniel S. Pereira, PhD, David R. Stover, PhD
Journal: Blood
Blood (2015) 126 (23): 3806.
https://doi.org/10.1182/blood.V126.23.3806.3806
Published: 2015